FDA Approves First mRNA Flu Vaccine, Moderna’s mFLUSIVA
FDA licensed mFLUSIVA for adults 50 and older on 5 August 2026 — a standard approval for ages 50–64 and an accelerated approval for 65 and up, pending a confirmatory trial. The clearance follows a February refusal-to-file that Moderna disputed and FDA reversed within two weeks.